Orforglipron is an oral medication that is currently being developed for type 2 diabetes and weight loss. It is a GLP-1 that is in early clinical trials.
Effectiveness
Convenience
Form
Tablet
Coming soon
Orforglipron (LY-3502970) is a small-molecule, non-peptide oral GLP-1 receptor agonist. Unlike current GLP-1 medications such as semaglutide (e.g. Wegovy, Ozempic) or tirzepatide (Mounjaro), which are injected and peptide-based, orforglipron is formulated as a tablet that can be taken once daily without any restrictions on food or water intake
Orforglipron mimics GLP-1, a naturally occurring gut hormone, by activating its receptor to:
Suppress appetite and reduce food intake
Lower blood glucose levels via enhanced insulin secretion and reduced glucagon
Slow gastric emptying, supporting glycemic control and weight loss
Even as a small molecule, it has shown efficacy comparable to injectable GLP-1s
What people are saying
